CAS 164656-23-9 Dutasteride - Analytical Products / Alfa Chemistry

CAT	APS164656239
CAS	164656-23-9
Structure
Synonyms	GI 206020X, GW 402836X, GI 198745X, GG 745, Dutasteride,1H-Indeno[5,4-f]quinoline-7-carboxamide, N-[2,5-bis(trifluoromethyl)phenyl]-2,4a,4b,5,6,6a,7,8,9,9a,9b,10,11,11a-tetradecahydro-4a,6a-dimethyl-2-oxo-, (4aR,4bS,6aS,7S,9aS,9bS,11aR)-, 4-Azaandrost-1-ene-17-carboxamide, N-[2,5-bis(trifluoromethyl)phenyl]-3-oxo-, (5alpha,17beta)-, Dutasteride, GW 403358X, (5alpha,17beta)-N-[(2,5-Bis(trifluoromethyl)phenyl]-3-oxo-4-aza-5-androst-1-ene-17-carboxamide, GW 504051X, Veltride, GW 402839X, Avolve, GI 246118X, Avodart, GI 198745, GW 418079X, GI 246071X
IUPAC Name	(1S,3aS,3bS,5aR,9aR,9bS,11aS)-N-[2,5-bis(trifluoromethyl)phenyl]-9a,11a-dimethyl-7-oxo-1,2,3,3a,3b,4,5,5a,6,9b,10,11-dodecahydroindeno[5,4-f]quinoline-1-carboxamide
Molecular Weight	528.53
Molecular Formula	C27H30F6N2O2
Canonical SMILES	C[C@]12CC[C@H]3[C@@H](CC[C@H]4NC(=O)C=C[C@]34C)[C@@H]1CC[C@@H]2C(=O)Nc5cc(ccc5C(F)(F)F)C(F)(F)F
InChI	InChI=1S/C27H30F6N2O2/c1-24-11-9-17-15(4-8-21-25(17,2)12-10-22(36)35-21)16(24)6-7-19(24)23(37)34-20-13-14(26(28,29)30)3-5-18(20)27(31,32)33/h3,5,10,12-13,15-17,19,21H,4,6-9,11H2,1-2H3,(H,34,37)(H,35,36)/t15-,16-,17-,19+,21+,24-,25+/m0/s1

Accurate Mass	528.2211
Format	Neat

* Products or Services Interested: Dutasteride (164656-23-9)
* Your question
* Name
* Email
Verification Code

CAT	Size	Shipping	Storage Conditions	Description	Price
APS164656239-150MG	150MG	Room Temperature	2-8°C Fridge/Coldroom	API Family: Matrix - API Family See respective official monograph(s); Product Type: API; Subcategory: European Pharmacopoeia (Ph. Eur.)	Inquiry
APS164656239-250MG	250MG	Room Temperature	+5°C	API Family: Matrix - API Family Dutasteride; Product Type: API; Subcategory: Mikromol, API standards, Anticancerous	Inquiry
APS164656239-10MG	10MG	Room Temperature	-20°C Freezer	Subcategory: Sports drugs and steroids, Enzyme inhibitors	Inquiry

Case Study

Dutasteride Used for the Preparation of Nanostructured Lipid Carriers via Melt-Dispersion Ultrasonication

Noor, Norhayati Mohamed, et al. European Journal of Pharmaceutics and Biopharmaceutics 117 (2017): 372-384.

Dutasteride, a poorly water-soluble 5α-reductase inhibitor, has been investigated for topical delivery through nanostructured lipid carriers (NLCs). In this experimental approach, dutasteride-loaded NLCs (DST-NLCs) were prepared using the melt-dispersion ultrasonication method, a process designed to achieve stable nanoscale formulations with enhanced drug incorporation.
The procedure commenced with the dissolution of dutasteride (5 mg) in a lipid phase consisting of stearic acid and Phosal 53 MCT, maintained at 80-90 °C under magnetic stirring until a clear solution was obtained. In parallel, an aqueous phase was prepared by dissolving Lutrol micro 68 in 10 mL of water at the same temperature. The two phases were combined and subjected to high-shear homogenization using an Ultra Turrax T25 operating at 19,000 rpm for 10 minutes.
The resulting hot emulsion was further processed via probe-type sonication (18 W, 5 minutes) to reduce particle size and ensure uniform dispersion. To induce nanoparticle formation, 2 mL of the hot dispersion was rapidly injected through a 25-gauge needle into 10 mL of cold water (4-8 °C) under continuous stirring. The nanoparticles were subsequently stabilized by stirring for an additional 10 minutes and stored at 4-8 °C for characterization.
This systematic preparation highlights how controlled heating, high-shear homogenization, and sonication synergistically facilitate the encapsulation of dutasteride within lipid-based nanocarriers suitable for topical applications.

Dutasteride Used for Elucidating Adverse Outcome Pathways in Zebrafish Embryos Through Steroid 5α-Reductase Inhibition

Cho, Hyunki, et al. Comparative Biochemistry and Physiology Part C: Toxicology & Pharmacology 287 (2025): 110048.

Dutasteride, a dual inhibitor of steroid 5α-reductase (SRD5A) isoforms 1 and 2, has been extensively applied in endocrine research to study androgen-estrogen interplay. In aquatic toxicology, it has served as a model compound for delineating adverse outcome pathways (AOPs) linking SRD5A inhibition to reproductive impairment.
In this experimental study, zebrafish embryos (Danio rerio) were exposed to dutasteride at concentrations of 0.005, 0.05, 0.5, and 2 μM from 72 to 120 hours post-fertilization under controlled conditions (28.0 ± 0.5 °C, 16/8 h light cycle). Daily renewal of the exposure medium ensured consistent drug levels while minimizing uptake-driven accumulation. Biochemical assays revealed dose-dependent reductions in dihydrotestosterone (DHT), 17β-estradiol (E2), and vitellogenin (VTG), each showing strong positive correlation. Gene expression analysis further demonstrated significant downregulation of srd5a2, cyp19a1, esr1, esr2a, esr2b, and vtg, confirming coordinated endocrine disruption.
Molecular docking suggested that dutasteride's effects are primarily mediated through suppression of DHT synthesis rather than direct receptor antagonism. Rescue experiments, in which embryos were co-exposed to dutasteride and exogenous DHT, restored gene expression to near-control levels, emphasizing DHT's central role in estrogenic function.
This case illustrates how dutasteride exposure provides mechanistic insights into vertebrate endocrine regulation and validates its utility in constructing AOP frameworks for reproductive toxicity. The findings contribute to bridging knowledge gaps on androgen-estrogen cross-talk in aquatic species.

Dutasteride Used for the Preparation of Sustained-Release Microsphere Microneedle Patches for Androgenetic Alopecia Treatment

Su, Xiaomeng, et al. Journal of Drug Delivery Science and Technology 111 (2025): 107179.

Dutasteride (DUT), a potent dual 5α-reductase inhibitor, plays a critical role in managing androgenetic alopecia (AGA) by lowering dihydrotestosterone (DHT) levels. Despite its clinical efficacy, conventional oral delivery is associated with systemic side effects and poor compliance. To overcome these limitations, a dissolving microneedle (MN) patch integrating dutasteride-loaded sustained-release microspheres (DUT-MS) was developed for localized, minimally invasive therapy.
DUT-MS was prepared by an oil-in-water (O/W) emulsion solvent evaporation method. Specifically, 10 mg DUT and 100 mg poly(lactic-co-glycolic acid) (PLGA) were dissolved in dichloromethane (DCM) as the oil phase, then emulsified into 1% polyvinyl alcohol (PVA) aqueous solution at 15,000 rpm. The mixture was stirred for four hours to evaporate solvents, followed by centrifugation and repeated washing. The resulting microspheres were lyophilized into a stable powder stored at 4 °C. These DUT-MS were subsequently loaded into the tips of dissolving MNs composed of hyaluronic acid (HA) and polyvinylpyrrolidone K30 (PVP K30).
Upon skin insertion, the microneedles dissolved rapidly, delivering DUT-MS into the dermis for sustained release. In a testosterone-induced AGA mouse model, weekly administration of DUT-MS-MNs maintained therapeutic efficacy comparable to daily treatment, highlighting improved compliance and reduced dosing frequency.
This case demonstrates how dutasteride can be engineered into advanced biomaterial-based delivery systems, offering a promising long-acting and localized therapeutic approach for AGA.